NICE drafts scope for Genzyme/Isis' Kynamro
This article was originally published in Scrip
NICE, the health technology appraisal institute for England and Wales, has released a draft scope for consultation of Genzyme/Isis Pharmaceuticals ' Kynamro (mipomersen sodium) for hypercholesterolaemia.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.